Zylö Therapeutics >>
zylotherapeutics.com
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$4.9M
8 rounds on record
Latest round
$1.5M
Venture round · Jul 2021 · 5 yr ago
Team
6
US Form 5500 (plan participants) · Dec 2024
Grants
$3.4M
6 grants · CORDIS
Backers
1
Boston Harbor Angels
The money's age
Long since its last round
63 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 12, 2025
Won a grant $300k · CORDIS
Jun 1, 2023
Won a grant $294k · CORDIS
Sep 15, 2022
Won a grant $263k · CORDIS
Aug 18, 2022
Won a grant $600k · CORDIS
Jul 19, 2021
Won a grant $1.7M · CORDIS
Sep 13, 2019
Won a grant $225k · CORDIS
May 24, 2019
Raised a round Venture round $3.4M · SEC Form D
2017
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Sep 2025 | $300k | — | CORDIS |
| Grant | Jun 2023 | $294k | — | CORDIS |
| Grant | Sep 2022 | $263k | — | CORDIS |
| Grant | Aug 2022 | $600k | — | CORDIS |
| Grant | Jul 2021 | $1.7M | — | CORDIS |
| Venture round | Jul 2021 | $1.5M | — | SEC Form D |
| Grant | Sep 2019 | $225k | — | CORDIS |
| Venture round | May 2019 | $3.4M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Zylo Therapeutics, LLC | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Scott PancoastExecutive Officer, DirectorSEC Form D
Thomas MurrayExecutive OfficerSEC Form D
Michael RabinExecutive OfficerSEC Form D
Charles HinkleExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Boston Harbor Angels Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
E-mailadres Wachtwoord Wachtwoord vergeten? Semble is powered by Cantrijn E-mailadres Wachtwoord Wachtwoord vergeten?
Miphic. Therapeutic targeting of mitochondria has a great potential in:.
Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
General Galactic builds advanced spacecraft for sustained maneuver and more time on-mission across the space domain.
News
Zylö Receives $294,000 NIH Phase I Grant to Advance its Cutaneous Lupus Program
Funds to be used to demonstrate efficacy in a new mouse model of cutaneous lupus GREENVILLE, SC, May 31, 2023 (GLOBE NEWSWIRE) -- Zylö Therapeutics...
Read more
Report
Zylö Receives $263,000 NIH Phase I Grant to Develop a Topical Viagra for ED
Funds to be used to optimize a formulation and demonstrate comparable efficacy to oral Viagra GREENVILLE, SC, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Zylö...
Read more
Report
Zylö Receives $600,000 NIH Phase I Grant to Develop a Novel Therapeutic to Treat Onychomycosis (Nail Fungus)
Funds to be used to optimize a formulation and prepare for scale-up and IND-enabling studies GREENVILLE, SC, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Zylö...
Read more
Report
Zylö Therapeutics Closes $5.225 Million Series B Financing
GREENVILLE, SC, June 03, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., dedicated to developing a transformational drug-delivery platform, announced that it has raised $5.225 million in its Series B financing. The Series B round was led by a consortium
Read more
Report
Zylö Therapeutics Closes $5.225 Million Series B Financing
GREENVILLE, SC, June 03, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., dedicated to developing a transformational drug-delivery platform, announced...
Read more
Report
Zylö's Erectile Dysfunction Product Concept Wins Best Abstract Award
The product concept uses patent-pending Z-pods to sustainably-for over an hour-release nitric oxide GREENVILLE, SC, Nov. 10, 2021 (GLOBE NEWSWIRE) -- A...
Read more
Report
Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials
Funds to be used for scale-up, implementation of cGMP quality system, and pre-IND FDA meeting GREENVILLE, SC, July 20, 2021 (GLOBE NEWSWIRE) --...
Read more
Report
Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI's Z-pod technology for the transdermal time released delivery of therapeutics
Sustained Transdermal Delivery Method May Be Key for Alzheimer's and Parkinson's Patients with Dysphagia (difficulty swallowing) ...
Read more
Report
Grapefruit USA, Inc. Announces Execution of New License Agreement with Zylö Therapeutics Inc. Expanding Grapefruit's Patented Hourglass Product line to include Hemp-Derived CBD Topical Delivery Creams For Nationwide Distribution
No other CBD products on Earth offer this advantage. The new license agreement grants Grapefruit exclusive rights to Zylö's patented time-release Z-Pod technology for THC+ Cannabinoid Topical Cream in the United States, Canada, and Mexico and non-exclusiv
Read more
Report
Hoth Therapeutics Expands Partnership with Zylö Therapeutics, Inc.
/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has completed a strategic investment in Zylö...
Read more
Report
Show more news
People
Scott Pancoast
Executive Officer, Director
Thomas Murray
Executive Officer
Michael Rabin
Executive Officer
Charles Hinkle
Executive Officer
Lance White
Director
Gary Atkinson
Director
James Cordes
Director
Matt Dunbar
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Greenville
United States
HQ
GET IN TOUCH
10-50 est. staff
105A Ben Hamby Rd., Greenville, SC 29615
Financials
Total raised
$8.3M
Latest round
Grant
Funding rounds
8